Bristol-Myers Squibb | BMY - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Abbott USD 10.46B 1.15B 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 12.22B 4.04B 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Drreddys Laboratories INR 74.33B 1.4B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.8B 468M 2026-06
J&J USD 17.83B 388M 2026-06
Medtronic USD 7.72B 436M 2026-03
Merck USD 18.17B 8.01B 2026-03
Novartis USD 10.2B 912M 2026-06
Novo Nordisk DKK 37.21B 9.56B 2026-03
Perrigo USD 935.6M 89.6M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 206.12M 5.17M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 9.31B 1.2B 2026-03
Sanofi EUR 8.98B 1.73B 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Zoetis USD 3.23B 1.68B 2026-03